Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenue:
Total revenue	$ 101,907	$ 152,915	$ 114,617
Operating costs and expenses:
Cost of goods sold	24,897	19,477	21,374
Research and development	400,269	408,678	434,566
General and administrative	122,844	104,682	98,712
Impairment of assets and other costs for terminated program	0	45,189	0
Total operating costs and expenses	548,010	578,026	554,652
Loss from operations	(446,103)	(425,111)	(440,035)
Non-operating income (expense):
Change in fair value of development derivative liability	(8,023)	0	0
Non-cash interest expense on liabilities related to the sales of future royalties	(47,313)	(30,267)	(25,044)
Loss on revaluation of liability related to the sale of future royalties	(24,410)	0	0
Interest income and other income (expense), net	2,569	18,282	46,335
Interest expense	0	(6,851)	(21,310)
Total non-operating expense, net	(77,177)	(18,836)	(19)
Loss before provision for income taxes	(523,280)	(443,947)	(440,054)
Provision for income taxes	557	493	613
Net loss	$ (523,837)	$ (444,440)	$ (440,667)
Net loss per share
Basic ( in dollars per share)	$ (2.86)	$ (2.49)	$ (2.52)
Diluted (in dollars per share)	$ (2.86)	$ (2.49)	$ (2.52)
Weighted average shares outstanding used in computing net loss per share
Basic (in shares)	183,298	178,581	174,993
Diluted (in shares)	183,298	178,581	174,993
Product sales
Revenue:
Total revenue	$ 23,725	$ 17,504	$ 20,117
Royalty revenue
Revenue:
Total revenue	0	30,999	41,222
Non-cash royalty revenue related to the sales of future royalties
Revenue:
Total revenue	77,746	48,563	36,303
License, collaboration and other revenue
Revenue:
Total revenue	$ 436	$ 55,849	$ 16,975